SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
EXOZ

Exozymes Inc. (NASDAQ:EXOZ)

US · Delayed Price · Currency is USD
Also listed: IZTCHealthcare · Biotechnology
$2.90-$0.47 (-14.05%)
 
Market cap
$27.4M
Insider Score
Health Score
Listed since
Nov 13, 2024
Market Cap$27.42M-81.3%
Revenue (ttm)$0
Net Income-$10.14M-21.6%
EPS-$1.17+4.1%
Shares Out9.44M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume10,823
Open$3.31
Previous Close$3.38
Day's Range$2.84 - $3.31
52-Week Range$2.81 - $16.16
Beta3.35
Analystsn/a
Price Targetn/a
Earnings DateMar 29, 2027
-13.91% (1D)
No price history available.

About EXOZ

eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia, California.

Address
750 Royal Oaks Drive, Monrovia, CA, 91016, US
Market Cap
27 million
Employees
32
Industrial Classification
Biotechnology

Exozymes Inc. Stock Analysis — InsiderScore

Insider Score
See top-rated InsiderScore stocks ›
29th Percentile Overall Score
EXOZ InsiderScore:58 / 99

Exozymes Inc. scored higher than 29% of companies evaluated by InsiderBuying, and ranked 62nd out of 107 stocks in the biotech sector.

Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.

Dollars Committed

Insiders at Exozymes Inc. bought $6.4K of stock across 5 purchases in the last 90 days, the largest of them $1.9K.

Stake Increase

The average purchase added about 1% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.

New Positions

Every buyer already held stock, so each purchase is an increase rather than a first position.

This category carries 35% of the Insider Score.

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$34.85K
Bought
$6.41K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Financial Health Score
Fair
From EXOZ’s reported statements · Q3 2026 (trailing 12 months) · 4 of 5 pillars

Next catalysts

1 Day
-14.05%
5 Days
-25.13%
1 Month
-25.51%
6 Months
-70.72%
1 Year
-81.25%

$EXOZ stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in EXOZ holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by EXOZ's directors and management

Net Shares Purchased by Insiders−4k−2k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

EXOZ Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New EXOZ patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to EXOZ from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in EXOZ

VTIVanguard Morningstar Total Stock Market ETF$281.16K
VXFVanguard Extended Market ETF$92.27K
IWCiShares Micro-Cap ETF$35.22K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from EXOZ’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
71% of score
54.2
Analyst Ratings
No data yet
—
News & Sentiment
29% of score
72

News check: Q3 earnings with new Curia manufacturing deal and DOE grant announced; concrete business developments outweigh general update announcements.

Recent Insider Activity

Buys
5
Sells
3
Buy Value
$6.41K
Distinct Buyers
1

Insider Score Trend Over Time

-13.3 since Sep 24
0255075100Sep 24 — Insider Score 69.6Sep 25 — Insider Score 78.4Sep 26 — Insider Score 78.3Sep 27 — Insider Score 78.4Sep 28 — Insider Score 78.3Sep 29 — Insider Score 77.8Sep 30 — Insider Score 77.5Oct 1 — Insider Score 77.1Oct 2 — Insider Score 40.0Oct 3 — Insider Score 76.7Oct 4 — Insider Score 76.8Oct 5 — Insider Score 77.0Oct 6 — Insider Score 76.6Oct 7 — Insider Score 76.3Oct 8 — Insider Score 76.3Oct 9 — Insider Score 76.9Oct 10 — Insider Score 76.7Oct 11 — Insider Score 77.0Oct 12 — Insider Score 76.9Oct 13 — Insider Score 76.8Oct 14 — Insider Score 76.5Oct 15 — Insider Score 76.4Oct 16 — Insider Score 76.2Oct 17 — Insider Score 76.1Oct 18 — Insider Score 76.3Oct 19 — Insider Score 76.3Oct 20 — Insider Score 75.9Oct 21 — Insider Score 76.0Oct 22 — Insider Score 76.0Oct 23 — Insider Score 76.0Oct 24 — Insider Score 76.1Oct 25 — Insider Score 75.6Oct 26 — Insider Score 75.8Oct 27 — Insider Score 75.6Oct 28 — Insider Score 75.6Oct 29 — Insider Score 75.1Oct 30 — Insider Score 73.9Oct 31 — Insider Score 73.6Nov 1 — Insider Score 73.0Nov 2 — Insider Score 72.3Nov 3 — Insider Score 71.1Nov 4 — Insider Score 71.3Nov 5 — Insider Score 70.7Nov 6 — Insider Score 69.5Nov 7 — Insider Score 67.9Nov 8 — Insider Score 68.6Nov 9 — Insider Score 68.9Nov 10 — Insider Score 67.9Nov 11 — Insider Score 67.2Nov 12 — Insider Score 67.0Nov 13 — Insider Score 65.5Nov 14 — Insider Score 64.3Nov 15 — Insider Score 64.7Nov 16 — Insider Score 64.2Nov 17 — Insider Score 61.2Nov 18 — Insider Score 59.7Nov 19 — Insider Score 58.3Nov 20 — Insider Score 58.0Nov 21 — Insider Score 57.0Nov 22 — Insider Score 56.3Sep 24Oct 23Nov 22

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.